MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 333122 | Name: Tenofovir S-isomer
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tenofovir S-isomer is the S-isomer of Tenofovir. Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI) with potent antiviral activity against HIV-1, HIV-2, and hepatitis B virus (HBV). It functions as an acyclic nucleotide analog of adenosine monophosphate, requiring intracellular phosphorylation to its active form, tenofovir diphosphate. This metabolite competitively inhibits viral reverse transcriptase by incorporating into viral DNA, causing chain termination. Tenofovir exhibits high specificity for viral polymerases over human DNA polymerases, contributing to its favorable safety profile. It is widely used in antiretroviral therapy (ART) and HBV treatment, often in prodrug forms such as tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) to enhance bioavailability.

Chemical Structure

Tenofovir S-isomer
Tenofovir S-isomer
CAS#147127-19-3 (S-isomer)

Theoretical Analysis

MedKoo Cat#: 333122

Name: Tenofovir S-isomer

CAS#: 147127-19-3 (S-isomer)

Chemical Formula: C9H14N5O4P

Exact Mass: 287.0783

Molecular Weight: 287.22

Elemental Analysis: C, 37.64; H, 4.91; N, 24.38; O, 22.28; P, 10.78

Price and Availability

Size Price Availability Quantity
1g USD 350.00 2 Weeks
2g USD 550.00 2 Weeks
5g USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
147127-20-6 (Tenofovir) 206184-49-8 (hydrate) 147127-19-3 (S-isomer)
Synonym
Tenofovir S-isomer; (S)-9-(2-Phosphonomethoxypropyl)adenine; (S)-PMPA;
IUPAC/Chemical Name
Phosphonic acid, P-[[(1S)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-
InChi Key
SGOIRFVFHAKUTI-LURJTMIESA-N
InChi Code
InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m0/s1
SMILES Code
C([C@@H](OCP(=O)(O)O)C)N1C=2C(N=C1)=C(N)N=CN2
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 287.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Liu SJ, Zhang X, Yan LJ, Wang HC, Ding ZN, Liu H, Pan GQ, Han CL, Tian BW, Dong ZR, Wang DX, Yan YC, Li T. Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis. J Cancer Res Clin Oncol. 2025 Feb 11;151(2):77. doi: 10.1007/s00432-025-06082-4. PMID: 39934513; PMCID: PMC11814049. 2: Cao L, Li L, Yang L, Zhou N, Zhang Y. Efficacy and safety of tenofovir and entecavir in patients with chronic hepatitis B-related cirrhosis: a systematic review and meta-analysis. Front Pharmacol. 2025 Jan 20;16:1507117. doi: 10.3389/fphar.2025.1507117. PMID: 39901944; PMCID: PMC11788386. 3: Di Perri G, Bonora S. Clinical Pharmacology of the Single Tablet Regimen Bictegravir/Emtricitabine/Tenofovir Alafenamide in the evolving era of antiretroviral therapies. New Microbiol. 2024 Nov;47(3):243-250. PMID: 39560035. 4: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Tenofovir. 2024 Nov 15. PMID: 30000609. 5: Bruzzesi E, Muccini C, Castagna A. Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment. Expert Opin Drug Metab Toxicol. 2024 Nov 13:1-8. doi: 10.1080/17425255.2024.2428820. Epub ahead of print. PMID: 39530796. 6: Felim RR, Hasan I, Nelwan EJ. Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report. Acta Med Indones. 2024 Jul;56(3):411-418. PMID: 39463105. 7: Gräfe M, Schäfer MS, Leithner C, Allers K, Schneider T, Algharably EEA, Kreutz R, Riemer TG. Neuropsychiatric adverse events in tenofovir disoproxil fumarate- and tenofovir alafenamide-based HIV therapy and prophylaxis: a systematic review and meta‑analysis. Pol Arch Intern Med. 2024 Nov 28;134(11):16861. doi: 10.20452/pamw.16861. Epub 2024 Oct 10. PMID: 39387623. 8: Rodrigo M, Hartley C, Wasuwanich P, Van T, Karnsakul W. From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B. Expert Rev Anti Infect Ther. 2024 Dec;22(12):1099-1106. doi: 10.1080/14787210.2024.2412991. Epub 2024 Oct 9. PMID: 39360716. 9: Yoo JJ, Jung EA, Kim SG, Kim YS, Kim MJ. Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis. J Int AIDS Soc. 2024 Sep;27(9):e26358. doi: 10.1002/jia2.26358. PMID: 39301685; PMCID: PMC11413498. 10: Peng JX, Wang LZ, Wang QT, Li HL, Lin LJ, He JM. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a reconstructed individual patient data meta-analysis. Front Pharmacol. 2024 Aug 22;15:1393861. doi: 10.3389/fphar.2024.1393861. PMID: 39239648; PMCID: PMC11374766. 11: Pak K, Ibrahim B, Saab S. Safety of Tenofovir Disoproxil Fumarate Among Breastfeeding Infants of Patients With Chronic Hepatitis B: A Systematic Review. J Viral Hepat. 2024 Nov;31(11):760-767. doi: 10.1111/jvh.14001. Epub 2024 Aug 29. PMID: 39206721. 12: Hu L, Yang C, Qiao Y, Wang A. A systematic review and meta-analysis comparing the impact of tenofovir and entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma patients undergoing liver resection. Front Pharmacol. 2024 Jul 29;15:1443551. doi: 10.3389/fphar.2024.1443551. PMID: 39135793; PMCID: PMC11317427. 13: Wu L, Niu X, Brunelli MK, Mugwanya KK. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review. Curr HIV/AIDS Rep. 2024 Oct;21(5):264-281. doi: 10.1007/s11904-024-00705-0. Epub 2024 Aug 9. PMID: 39120667. 14: Lumley SF, Delphin M, Mokaya JF, Tan CCS, Martyn E, Anderson M, Li KC, Waddilove E, Sukali G, Downs LO, Said K, Okanda D, Campbell C, Harriss E, Shimakawa Y, Matthews PC. A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir. J Clin Virol. 2024 Oct;174:105711. doi: 10.1016/j.jcv.2024.105711. Epub 2024 Jun 28. Erratum in: J Clin Virol. 2024 Oct;174:105716. doi: 10.1016/j.jcv.2024.105716. PMID: 38991458. 15: Eke AC, Ramaiyer M, Eleje GU, Ezebialu IU, Aliyu MH. A systematic review and meta-analysis of maternal weight changes and pregnancy outcomes associated with integrase inhibitors and tenofovir alafenamide in pregnant women with HIV. Am J Obstet Gynecol MFM. 2024 Aug;6(8):101406. doi: 10.1016/j.ajogmf.2024.101406. Epub 2024 Jun 10. PMID: 38866134; PMCID: PMC11719166. 16: Pan CQ, Zhu L, Yu AS, Zhao Y, Zhu B, Dai E. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Preventing Vertical Transmission in Chronic Hepatitis B Mothers: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2024 Oct 15;79(4):953-964. doi: 10.1093/cid/ciae288. PMID: 38805690; PMCID: PMC11478587. 17: Chivite I, Berrocal L, de Lazzari E, Navadeh S, Lluis-Ganella C, Inciarte A, de la Mora L, González-Cordón A, Martínez-Rebollar M, Laguno M, Torres B, Blanco JL, Martínez E, Mallolas J, Ambrosioni J. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis. J Antimicrob Chemother. 2024 Aug 1;79(8):1775-1783. doi: 10.1093/jac/dkae138. PMID: 38758191. 18: Zhao F, Lu H. Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review. Biosci Trends. 2024 Jun 6;18(2):141-152. doi: 10.5582/bst.2024.01062. Epub 2024 Apr 24. PMID: 38658364. 19: Buzon-Martin L, Navarro-San Francisco C, Fernandez-Regueras M, Sanchez-Gomez L. Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature. J Antimicrob Chemother. 2024 May 2;79(5):1153-1156. doi: 10.1093/jac/dkae085. PMID: 38558010. 20: Hashwin Singh TS, Jashwin Singh TS, Chin KY. Effects of Tenofovir Disoproxil Fumarate on Bone Quality beyond Bone Density-A Scoping Review of the Literature. Pharmaceuticals (Basel). 2024 Jan 23;17(2):146. doi: 10.3390/ph17020146. PMID: 38399361; PMCID: PMC10891525.